Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ThirdGate Capital
Charlottesville, Virginia, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
ThirdGate Capital is a boutique investment and advisory firm specializing in the healthcare and life sciences industries. Based in Charlottesville, Virginia, the firm focuses on identifying and developing high-value opportunities within biotechnology and pharmaceuticals. It is closely integrated with the leadership of Biovista, utilizing advanced data analytics and systematic drug repositioning strategies to evaluate therapeutic assets. ThirdGate Capital provides strategic guidance on clinical development, regulatory pathways, and market positioning for its portfolio interests and clients. The firm leverages deep domain expertise to bridge the gap between scientific innovation and commercial success. Its activities often involve scouting for undervalued drug candidates that can be repurposed for new indications.
- Industry
- Investors
02
Partnerships
Biovista
Beyond the preview
Go deeper on ThirdGate Capital.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ThirdGate Capital.